Search for Terms or Answers
Randomized trials typically get top billing at ACR Convergence, but the past three years have seen “target trial emulations” land coveted plenary sessions and oral abstracts. These are not actually trials; instead, they are a new-ish approach to generating causal inferences from observational
For my take on what has happened with zola-cel safety and what it tells us about interpreting CAR-T safety in general, check out my #ACR26 article @RheumNow: https://t.co/mGZmOsoE8o
BREAKING: Reports that Novartis still working on IEC-HS investigation after rap-cel CAR-T deaths. Georg Schett calls lack of details "very sad" & has submitted commentary to @NEJM (with Carl June, CAR-T inventor) to discuss it https://t.co/Tn2svGi0BP #ACR26 @RheumNow https://t.co/5ZJ8pGCQg7
Zeng et al. TARA phase 3 RCT from China. 459 bDMARD-IR patients. Girocitinib (JAK1/TYK2i) superior to tofacitinib in RA. Better by week 4 and increasingly so over time. Numerically less serious adverse events 3.9% vs 6.6% also. @RheumNow #ACR26 Abstr#LB21 #ACRbest https://t.co/Yt406T3eyi
The first multicenter series of pregnancies after CAR T-cell therapy for autoimmune disease reports 8 healthy births and no maternal flares. It is the first dataset of its kind, and the numbers are small.
FASTLANE study: Significantly higher proportion of pts w/early active axSpA on Tofa 5mg BID/naproxen achieved ASDAS inactive dse vs. PBO/naproxen at wk 16 (26.4% vs. 7% p0.006) AEs occured in 50% of pts on TOFA vs. 33% on PBO. AEs: infections, GI @RheumNow #ACR26 Abs2314 #ACRbest https://t.co/QkxaNCDQsu
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.